Abstracts tagged "inflammatory myositis and interstitial lung disease"

Abstract Number: 2135 • 2017 ACR/ARHP Annual Meeting
ADAM-17 Is Expressed in the Inflammatory Myopathy, and Is Involved with Interstitial Lung Disease
Airi Nishimi, Takeo Isozaki, Shinichiro Nishimi, Sho Ishii, Takahiro Tokunaga, Hidekazu Furuya, Kuninobu Wakabayashi and Tsuyoshi Kasama, Div of Rheumatology, Showa University School of Med, Shinagawa-ku Tokyo, Japan
Background/Purpose: A disintegrin and metalloprotesase (ADAM) family is protease that is thought to have an important role in tissue destruction and inflammatory reaction. ADAMs are…
Abstract Number: 2175 • 2017 ACR/ARHP Annual Meeting
Novel Assessment of Interstitial Lung Disease Using the “Computer-Aided Lung Informatics for Pathology Evaluation and Rating” Software System in Idiopathic Inflammatory Myopathies
Patompong Ungprasert¹, Katelynn Wilton², Floranne C. Ernste³, Sanjay Kalra⁴, Cynthia S. Crowson⁵, Srinivasan Rajagopalan⁶ and Brian Bartholmai⁷, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Immunology, Mayo Clinic, Rochester, MN, ³Division of Rheumatology, Mayo Clinic Rochester, Rochester, MN, ⁴Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, ⁵Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁶Mayo Clinic, Rochester, MN, ⁷Thoracic Radiology, Mayo Clinic, Rochester, MN
Background/Purpose: The idiopathic inflammatory myopathies (IIM) are often associated with interstitial lung diseases (ILD). Yet, pulmonary function testing (PFT) results can be confounded by patient…
Abstract Number: 1266 • 2014 ACR/ARHP Annual Meeting
Anti-MDA5 Is Associated with Rapidly-Progressive Interstitial Lung Disease and Poor Survival in U.S. Patients with Amyopathic and Myopathic Dermatomyositis
Siamak Moghadam-Kia¹, Chester V. Oddis², Shinji Sato³, Masataka Kuwana⁴ and Rohit Aggarwal¹, ¹Medicine, University of Pittsburgh, Pittsburgh, PA, ²Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ³Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose : Clinically amyopathic dermatomyositis (CADM) is a subset of dermatomyositis (DM) presenting with the characteristic rash(es) of DM without objective muscle weakness. Asian studies…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].